Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Griffith

Showing results (141-150 of 511) with videos related to

Pageof 52
Sort By:
Archiv Fur Tierernahrung|September 1, 1987
The effects of frequency of feeding on some quantitative aspects of digestion in the rumens of growing steersA B McAllan, P E Lewis, E S Griffith
Diabetes Care|September 1, 1988
Depression in adults with diabetes. Results of 5-yr follow-up studyP J Lustman, L S Griffith, R E Clouse
Experimental Biology and Medicine (Maywood, N.J.)|September 17, 2016
Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of diseaseJavier Cabrera-Perez, Vladimir P Badovinac, Thomas S Griffith
International Reviews of Immunology|November 12, 2002
Cell death and immune privilegeThomas A Ferguson, Douglas R Green, Thomas S Griffith
Gastrointestinal Endoscopy|March 17, 1999
Gauze and washcloth insertion into the rectum during colonoscopy: an unrecognized complication?G S Griffith, C A Petruff, J S Barkin
Annals of Internal Medicine|February 1, 1991
Erythrocytosis after zidovudine for AIDSC A Kennedy, H S Griffith, G E Mathisen
Phytopathology|October 24, 2008
Charles lee campbell, 1953 to 1999Turner B Sutton, Paul D Peterson, Clay S Griffith
Apoptosis : an International Journal on Programmed Cell Death|December 30, 2006
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activityRebecca L VanOosten, James K Earel, Thomas S Griffith
Pacing and Clinical Electrophysiology : PACE|June 1, 1991
The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillationT Guarnieri, G Tomaselli, L S Griffith, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancerHenry M Rosevear, Andrew J Lightfoot, Thomas S Griffith
Pageof 52

Showing results (141-150 of 511) with videos related to

Sort By:
Pageof 52
Archiv Fur Tierernahrung|September 1, 1987
The effects of frequency of feeding on some quantitative aspects of digestion in the rumens of growing steersA B McAllan, P E Lewis, E S Griffith
Diabetes Care|September 1, 1988
Depression in adults with diabetes. Results of 5-yr follow-up studyP J Lustman, L S Griffith, R E Clouse
Experimental Biology and Medicine (Maywood, N.J.)|September 17, 2016
Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of diseaseJavier Cabrera-Perez, Vladimir P Badovinac, Thomas S Griffith
International Reviews of Immunology|November 12, 2002
Cell death and immune privilegeThomas A Ferguson, Douglas R Green, Thomas S Griffith
Gastrointestinal Endoscopy|March 17, 1999
Gauze and washcloth insertion into the rectum during colonoscopy: an unrecognized complication?G S Griffith, C A Petruff, J S Barkin
Annals of Internal Medicine|February 1, 1991
Erythrocytosis after zidovudine for AIDSC A Kennedy, H S Griffith, G E Mathisen
Phytopathology|October 24, 2008
Charles lee campbell, 1953 to 1999Turner B Sutton, Paul D Peterson, Clay S Griffith
Apoptosis : an International Journal on Programmed Cell Death|December 30, 2006
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activityRebecca L VanOosten, James K Earel, Thomas S Griffith
Pacing and Clinical Electrophysiology : PACE|June 1, 1991
The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillationT Guarnieri, G Tomaselli, L S Griffith, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancerHenry M Rosevear, Andrew J Lightfoot, Thomas S Griffith
Pageof 52